Search results
13 mar 2018 · Memantine (MEM), an antagonist of extrasynaptic NMDAR, is currently used for the treatment of AD jointly with acetylcholinesterase inhibitors. It has been demonstrated that MEM preferentially prevents the excessive continuous extrasynaptic NMDAR disease activation and therefore prevents neuronal cell death induced by excitotoxicity without ...
- Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
Memantine, an NMDA receptor antagonist has been found to be...
- Memantine for Alzheimer's Disease: An Updated Systematic ... - PubMed
The meta-analyses suggest the credible efficacy and safety...
- The efficacy and safety of memantine for the treatment of ... - PubMed
Expert opinion: Memantine improves cognitive functions and...
- Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
2 mar 2007 · Memantine, an NMDA receptor antagonist has been found to be effective, both as monotherapy and in combination with donepezil, in the treatment of patients with moderate to severe stage AD.
6 cze 2023 · Memantine is a noncompetitive moderate‐affinity strong voltage‐dependent N‐methyl‐D‐aspartate receptor antagonist. It has been used to treat Alzheimer's disease (AD) since 1989. In 2018, it became the second most commonly used drug for the treatment of dementia in the world.
8 mar 2012 · Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the ...
The meta-analyses suggest the credible efficacy and safety of memantine in treating AD when used alone or in combination with ChEIs.
27 gru 2018 · Memantine showed the best profile of acceptability. Rivastigmine transdermal 15-cm2 patch was the best optional treatment both in function and global changes. None of the medicines was likely to improve neuropsychiatric symptoms through this analysis.
Expert opinion: Memantine improves cognitive functions and behavioral disturbances more efficiently than the placebo, both as monotherapy and in combination with donepezil.
